Brand Name
Koselugo
Generic Name
Selumetinib
View Brand Information FDA approval date: April 16, 2020
Classification: Kinase Inhibitor
Form: Granule, Capsule
What is Koselugo (Selumetinib)?
KOSELUGO is indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas . KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Summary: This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes ...
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Summary: This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment t...
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Summary: This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell gro...
Related Latest Advances
Brand Information
KOSELUGO (SELUMETINIB)
1INDICATIONS AND USAGE
KOSELUGO is indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
2DOSAGE FORMS AND STRENGTHS
Capsules:
- 10 mg selumetinib: white to off-white, opaque, hard capsule sealed with a clear band and marked with “SEL 10” in black ink.
- 25 mg selumetinib: blue, opaque, hard capsule sealed with a clear band and marked with “SEL 25” in black ink.
Oral Granules:
- 5 mg selumetinib: Off-white to light-yellow free-flowing oral granules contained within capsules. The capsules have a yellow cap and white body. The cap is printed with “sel 5” in black ink, and body is printed with a sprinkle capsule image indicating opening.
- 7.5 mg selumetinib: Off-white to light-yellow free-flowing oral granules contained within capsules. The capsules have a pink cap and white body. The cap is printed with “sel 7.5” in black ink, and body is printed with a sprinkle capsule image indicating opening.
3CONTRAINDICATIONS
None.
4ADVERSE REACTIONS
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Cardiomyopathy
- Ocular toxicity
- Gastrointestinal toxicity
- Skin toxicity
- Increased creatine phosphokinase
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to KOSELUGO in 134 pediatric patients at the recommended dose in SPRINKLE (N = 36) (NCT05309668), in SPRINT Phase I (N = 24), SPRINT Phase II Stratum 1 (N = 50), and Phase I Food Effect Study (N = 24). Among the 134 pediatric patients, the duration of KOSELUGO exposure, including dose interruptions, was 12 months or longer (80%), more than 2 years (44%), or more than 3 years (37%). In this pooled safety population, the most common adverse reactions of any grade (incidence ≥ 40%) were vomiting (64%), diarrhea (59%), increased creatine phosphokinase (55%), dry skin (51%), paronychia (50%), nausea (49%), dermatitis acneiform (47%), and pyrexia (46%).
Neurofibromatosis Type 1 (NF1) with Inoperable Plexiform Neurofibromas (PN)
Pediatrics 2 18 years of Age (SPRINT Phase II Stratum 1)
The safety of KOSELUGO was evaluated in SPRINT Phase II Stratum 1
Serious adverse reactions occurred in 24% of patients who received KOSELUGO. Serious adverse reactions that occurred in 2 or more patients were anemia, hypoxia and diarrhea.
Permanent discontinuation due to an adverse reaction occurred in 12% of patients who received KOSELUGO. Adverse reactions resulting in permanent discontinuation of KOSELUGO included increased blood creatinine, increased weight, diarrhea, paronychia, malignant peripheral nerve sheath tumor, acute kidney injury, and skin ulcer.
Dosage interruptions and dose reductions due to adverse reactions occurred in 80% and 24% of patients who received KOSELUGO, respectively. Adverse reactions requiring a dosage interruption or reduction in ≥ 5% of patients were vomiting, paronychia, diarrhea, nausea, abdominal pain, rash, skin infection, influenza like illness, pyrexia and weight gain.
The most common adverse reactions (≥ 40%) were vomiting, rash (all), abdominal pain, diarrhea, nausea, dry skin, fatigue, musculoskeletal pain, pyrexia, acneiform rash, stomatitis, headache, paronychia, and pruritus.
Table 10 presents the adverse reactions in SPRINT Phase II Stratum 1.
Clinically relevant adverse reactions that occurred < 20% of patients include:
- Eye: visual impairment
- Gastrointestinal Disorders: dry mouth
- General Disorders: facial edema, including periorbital edema and face edema
- Metabolism and Nutrition: increased weight
- Renal and Urinary System: acute kidney injury
- Respiratory, Thoracic & Mediastinal: dyspnea, including exertional dyspnea and dyspnea at rest
- Vascular: hypertension
Table 11 presents the laboratory abnormalities in SPRINT Phase II Stratum 1.
Pediatrics > 1 year of Age on KOSELUGO Granules (SPRINKLE)
The safety of KOSELUGO oral granules was evaluated in SPRINKLE (NCT05309668), a dose-finding and activity estimating, single-arm, multicenter study in 36 pediatric patients ages 1 year to less than 7 years with a clinical diagnosis of NF1-related symptomatic, inoperable PN. The study evaluated the pharmacokinetics (PK), safety, efficacy, and tolerability of KOSELUGO oral granules. Study patients were to receive KOSELUGO oral granules for 25 cycles at a dose equivalent to 25 mg/m
In the SPRINKLE study, the median duration of KOSELUGO oral granules treatment in pediatric patients with neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN) was 11 months (range: 3 25 months). Serious adverse reactions occurred in 6% of patients who received KOSELUGO oral granules. Serious adverse reactions occurred in 1 patient each and included pyrexia, gastroenteritis and upper respiratory infection. A total of 31% of patients had an adverse reaction leading to a dosage interruption. Adverse reactions requiring a dosage interruption in ≥ 5% of patients were pyrexia, vomiting, diarrhea, upper respiratory infection, gastroenteritis and eczema. The most common adverse reactions (≥ 40%) were pyrexia, dry skin, and paronychia.
The observed safety profile of KOSELUGO oral granules in the SPRINKLE study was consistent with the known safety profile of KOSELUGO capsules.
5OVERDOSAGE
Dialysis is not helpful as KOSELUGO is highly protein bound and is extensively metabolized.
6DESCRIPTION
KOSELUGO contains selumetinib sulfate, a kinase inhibitor. The chemical name is 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-6-[(2-hydroxyethoxy)carbamoyl]-1-methyl-1
Selumetinib sulfate is a white to yellow monomorphic crystalline powder that exhibits a pH dependent solubility. Selumetinib sulfate is freely soluble at pH < 1.5, sparingly soluble in the pH range at 1.5 to 3 and slightly soluble at pH > 3. Selumetinib sulfate has two ionizable functions with pKa values of 2.8 and 8.4.
KOSELUGO (selumetinib) 10 mg capsules for oral use, contain 10 mg selumetinib (equivalent to 12.1 mg selumetinib sulfate) and the excipient, vitamin E polyethylene glycol succinate. The capsule shell contains carnauba wax, carrageenan, hypromellose, potassium chloride, purified water, and titanium dioxide. The capsule is imprinted with black ink that contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
KOSELUGO (selumetinib) 25 mg capsules for oral use, contain 25 mg selumetinib (equivalent to 30.25 mg selumetinib sulfate) and the excipient, vitamin E polyethylene glycol succinate. The capsule shell contains carnauba wax and/or cornstarch, carrageenan, FD&C blue 2, ferric oxide yellow, hypromellose, potassium chloride, purified water, and titanium dioxide. The capsule is imprinted with black ink that contains carnauba wax, FD&C Blue 2 aluminum lake, ferric oxide red, ferric oxide yellow, glyceryl monooleate, and shellac.
KOSELUGO (selumetinib) 5 mg oral granules contain 5 mg selumetinib (equivalent to 6.05 mg selumetinib sulfate). The uncoated cores contain selumetinib sulfate, glyceryl dibehenate, and stearoyl polyoxylglycerides. The granule coating contains acetone, hypromellose acetate succinate, and stearic acid. The capsule shell contains ferric oxide yellow, hypromellose, and titanium dioxide. The capsule shell is imprinted with black ink that contains butyl alcohol, dehydrated alcohol, ferric oxide black, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution.
KOSELUGO (selumetinib) 7.5 mg oral granules contain 7.5 mg selumetinib (equivalent to 9.08 mg selumetinib sulfate). The uncoated cores contain selumetinib sulfate, glyceryl dibehenate, and stearoyl polyoxylglycerides. The granule coating contains acetone, hypromellose acetate succinate, and stearic acid. The capsule shell contains ferric oxide red, hypromellose, and titanium dioxide. The capsule shell is imprinted with black ink that contains butyl alcohol, dehydrated alcohol, ferric oxide black, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution.
7HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
Selumetinib Capsules
Selumetinib Oral Granules
Storage
KOSELUGO Capsules
Store KOSELUGO capsules at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Dispense and store in the original bottle to protect from light and moisture. Do not remove desiccant. Keep the bottle tightly closed after first opening.
KOSELUGO Oral Granules
Store and transport KOSELUGO oral granules refrigerated at 2°C to 8°C (36°F to 46°F). After receipt, patients may store at room temperature 20°C to 25°C (68°F to 77°F). Do NOT exceed 30°C (86°F). KOSELUGO oral granules may clump together or stick to the capsule shell if exposed to high temperatures, which may lead to underdose. Dispense and store in the original bottle to protect from light and moisture. Do not remove desiccant. Keep the bottle tightly closed after first opening.
8PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Cardiomyopathy
Advise patients and caregivers that KOSELUGO can cause a reduction in LVEF and to immediately report any signs or symptoms of cardiomyopathy to their healthcare provider
Ocular Toxicity
Advise patients and caregivers that KOSELUGO can cause ocular toxicity that can lead to blindness and to contact their healthcare provider if the patient experiences any changes in their vision
Gastrointestinal Toxicity
Advise patients and caregivers that KOSELUGO can cause diarrhea and to contact their healthcare provider at the onset of diarrhea
Skin Toxicity
Advise patients and caregivers that KOSELUGO can cause serious skin toxicities and to contact their healthcare provider for severe skin changes
Increased Creatine Phosphokinase
Advise patients and caregivers that KOSELUGO can cause increased CPK and to report any signs and symptoms of muscle pain or weakness to their healthcare provider
Increased Vitamin E Levels and Risk of Bleeding
Advise patients and caregivers to notify their healthcare provider if they are taking a supplement containing vitamin E, a vitamin-K antagonist or an anti-platelet agent
Embryo-Fetal Toxicity
- Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy
- Advise females of reproductive potential to use effective contraception during treatment with KOSELUGO and for 1 week after the last dose
- Advise males with female partners of reproductive potential to use effective contraception during treatment with KOSELUGO and for 1 week after the last dose
Lactation
Advise women not to breastfeed during treatment with KOSELUGO and for 1 week after the last dose
Drug Interactions
Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John’s wort, grapefruit or grapefruit juice while taking KOSELUGO
Dosing and Administration
Inform patients and caregivers on how to take KOSELUGO and what to do for missed or vomited doses
Distributed by:
AstraZeneca Pharmaceuticals LP
Wilmington, DE 19850
© AstraZeneca 2025
9Instructions for Use
This Instructions for Use has been approved by the U.S. Food and Drug Administration. approved: Sep/2025
10PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 10mg
NDC 0310-0610-28
Koselugo
(selumetinib)
capsules
10 mg
Rx only
Dispense in original bottle.
desiccant. Protect from moisture.
Keep the bottle tightly closed.
28 Capsules AstraZeneca
11PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 25mg
NDC 0310-0625-28
Koselugo
(selumetinib)
capsules
25 mg
Rx only
Dispense in original bottle.
desiccant. Protect from moisture.
Keep the bottle tightly closed.
28 Capsules AstraZeneca
12Package/Label Display Panel 5 mg
NDC 0310-0635-60
Koselugo
(selumetinib)
Oral granules
7.5 mg
Sprinkle oral granules on or mix
with smooth yogurt or fruit puree.
Dispense and store in original
bottle
protect from light and moisture.
60 Capsules
Rx only Astrazeneca
13Package/Label Display Panel 7.5 mg
NDC 0310-0640-60
Koselugo®
(selumetinib)
Oral granules
7.5 mg
Sprinkle oral granules on or mix
with smooth yogurt or fruit puree.
Dispense and store in original
bottle
protect from light and moisture.
60 Capsules
Rx only Astrazeneca
